College Hill Life Sciences Grows Client Base in Australia
1 September 2011, London, Manchester, Munich, Sydney, Boston: The Life Sciences team of College Hill – the international business communications consultancy – continues to grow its client base in Australia, adding listed stem cell company Mesoblast and leading venture capital firm Brandon Capital most recently. The team now has substantial experience working with some of the leading players and most promising newcomers in the Australian market including:
Mesoblast (ASX: MSB; OTC ADR: MBLTY) – the world’s leading developer of innovative biological products for the broad field of regenerative medicine.
Phylogica (ASX:PYC) – a leading peptide drug discovery company that utilises proprietary Phylomer®peptide libraries and screening methodologies to identify unique peptide drug candidates for its pharmaceutical and biotechnology partners – operates internationally with headquarters in Perth, Australia.
Benitec (ASX:BLT) – a world leader in RNA-based gene silencing for human therapeutics. College Hill is retained to provide global and local strategic PR and IR counsel, and positioning.
Brandon Capital – a leading life science specialist venture capital firm, with over AU$100 million under management including the innovative Medical Research Commercialisation Fund (MRCF)Clinical Network Services (CNS) – a full service Australian CRO, specialising in Phase I and Phase II clinical development.
CIMTECH – an Australian-based early stage natural products company, developing products based on plants indigenous to the Cook Islands.
Elastagen – a clinical stage medical device company that is pioneering Elastatherapy™ using the human protein Elastin to naturally repair and augment the skin.
The i3 institute at the University of Technology Sydney (UTS) – a research institute focused on innovation, infection and immunity.
College Hill Life Sciences has previous experience working with a range of Australian companies including Biota, Clinuvel, Acrux, Phosphagenics, Virax and Proteome Systems.
Commenting on the Australian industry Sue Charles, Managing Partner, Life Sciences said: "Australia is a powerhouse of life science companies with some 450 biotechnology companies and 600 medical technology companies. With over 100 of those listed on the Australian stock exchange, this represents a maturing and rapidly internationalising industry in need of global communications support. We are delighted to be the leading agency providing truly international communications support to the Australian life science market.”
For further information:
Sue Charles, Managing Partner
UK: +44 (0)20 7457 2020/ +44 (0)7968 726 585
Australia: +61 (0)457 196 222
back to news